Akebia Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Akebia Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $0 | Mar 14, 2016 |
| FY2014 | Dec 31, 2014 | $0 | Mar 4, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $236.20M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $160.18M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $194.62M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $292.48M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $211.65M | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | $294.64M | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | $335.00M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $207.74M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $181.23M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $1.54M | Mar 26, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.35M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($69.41M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($51.93M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($94.23M) | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | ($54.10M) | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | $29.45M | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | ($63.51M) | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | ($282.02M) | Aug 28, 2023 |
| FY2020 | Dec 31, 2020 | ($87.00M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($59.96M) | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.50M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($50.47M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($46.26M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($80.78M) | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | ($50.40M) | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | $34.08M | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | ($59.58M) | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | ($264.50M) | Aug 28, 2023 |
| FY2020 | Dec 31, 2020 | ($85.40M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($58.10M) | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.36M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $37.65M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $63.08M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $129.99M | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | $28.03M | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | $147.85M | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | $218.49M | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | $322.97M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $291.01M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $230.89M | Mar 12, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.48M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $106.55M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $100.23M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $138.60M | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | $31.89M | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | $32.24M | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | $44.57M | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | $174.14M | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | $154.10M | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | $149.46M | Mar 1, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.99M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($40.66M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($23.38M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($73.15M) | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | ($18.48M) | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | ($52.28M) | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | ($21.62M) | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | ($252.97M) | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | ($110.39M) | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | ($257.44M) | Mar 1, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $291.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $33.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $0 | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $114.0K | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $59.0K | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | $317.0K | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | $6.66M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $1.61M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $1.62M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $2.66M | Mar 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $376.57M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $220.67M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $241.70M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $356.05M | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | $444.25M | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | $529.88M | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | $541.80M | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | $529.35M | Aug 28, 2023 |
| FY2021 | Dec 31, 2020 | $644.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $771.20M | Feb 25, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.96M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $269.86M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $272.29M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $350.82M | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | $435.99M | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | $470.95M | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | $519.22M | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | $455.34M | Aug 28, 2023 |
| FY2021 | Dec 31, 2020 | $396.52M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $376.44M | Feb 25, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.61M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($49.19M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($30.58M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $5.23M | Feb 26, 2026 |
| FY2023 | Dec 31, 2021 | $74.01M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $244.35M | Aug 28, 2023 |
| FY2022 | Dec 31, 2019 | $392.88M | Aug 28, 2023 |
| FY2021 | Dec 31, 2018 | $635.93M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $122.57M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $68.12M | Mar 12, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.04M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $59.04M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $59.04M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $59.04M | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | $59.04M | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | $59.04M | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | $59.04M | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | $59.04M | Aug 28, 2023 |
| FY2021 | Dec 31, 2020 | $55.05M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $55.05M | Feb 25, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.68B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($1.68B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($1.61B) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($1.56B) | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | ($1.55B) | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | ($1.50B) | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | ($1.53B) | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | ($1.46B) | Aug 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.18B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($794.05M) | Feb 25, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $51.87M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $42.93M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $90.47M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $149.80M | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | $228.70M | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | $147.45M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $104.64M | Feb 25, 2021 |
| FY2020 | Dec 31, 2017 | $70.16M | Feb 25, 2021 |
| FY2019 | Dec 31, 2016 | $187.34M | Mar 12, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.25M | Feb 26, 2026 |
| FY2024 | Dec 31, 2024 | $38.69M | Mar 13, 2025 |
| FY2023 | Dec 31, 2023 | $34.68M | Mar 14, 2024 |
| FY2022 | Dec 31, 2022 | $66.08M | Aug 28, 2023 |
| FY2021 | Dec 31, 2021 | $97.54M | Mar 1, 2022 |
| FY2020 | Dec 31, 2020 | $96.38M | Feb 25, 2021 |
| FY2019 | Dec 31, 2019 | $75.81M | Mar 12, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | (2) | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
| FY2022 | Sep 30, 2022 | 0 | Aug 28, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Aug 28, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Aug 28, 2023 |
| FY2022 | Dec 31, 2021 | (1) | Aug 28, 2023 |
| FY2022 | Dec 31, 2020 | (2) | Aug 28, 2023 |
| FY2021 | Dec 31, 2019 | (2) | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 265.42M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 224.85M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 194.58M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 184.14M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 177.00M | Aug 28, 2023 |
| FY2021 | Dec 31, 2020 | 148.07M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 121.67M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 116.89M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 47.61M | Mar 26, 2019 |
| FY2017 | Dec 31, 2016 | 38.62M | Mar 12, 2018 |